摘要
二肽基肽酶4(DPP4)抑制剂与钠-葡萄糖协同转运蛋白2(SGLT-2)抑制剂均已被批准用于治疗2型糖尿病(T2DM)。研究显示,DPP-4抑制剂对肾脏组织结构受损具有潜在的改善作用,而SGLT-2抑制剂则可通过改善肾脏血流动力学而发挥肾脏保护作用。因此,DPP-4抑制剂与SGLT-2抑制剂联合治疗不仅可改善代谢控制水平,而且对于T2DM患者的肾脏结构和功能具有潜在的协同保护作用。这种联合治疗策略为改善T2DM患者综合管理水平提供了新的选择。
Both dipeptidyl peptidase-4 ( DPP-4 ) inhibitor and sodium-glucose cotransporter-2 ( SGLT-2 ) inhibitor have been approved for the treatment of type 2 diabetes mellitus( T2DM). In preclinical or clinical studies, DPP-4 inhibitor shows a potential beneficial effect on renal architecture damage, whereas SGLT-2 inhibitor has a role in renoprotection by improving renal hemodynamics. Therefore, the combination therapies with DPP-4 inhibitor and SGLT-2 inhibitor not only improve metabolic control, but also may have a synergistic or complementary effect in protecting renal structure and function in patients with T2DM. This combination therapy provides a novel option for raising the comprehensive management level in patients with T2DM.
出处
《中华内分泌代谢杂志》
CAS
CSCD
北大核心
2017年第11期993-996,共4页
Chinese Journal of Endocrinology and Metabolism